|LyGDI is a Promising Biomarker for Ovarian Cancer|
|Zhen, Hongying2; Yang, Shaomin3; Wu, Hounan4; Wang, Shuling2; Lv, Jingqiao5; Ma, Lijun6; Zhang, Xiaowei1|
|关键词||Lygdi Ovarian Cancer Serum Tumor Marker|
|刊名||INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER|
|WOS标题词||Science & Technology|
|类目[WOS]||Oncology ; Obstetrics & Gynecology|
|研究领域[WOS]||Oncology ; Obstetrics & Gynecology|
|关键词[WOS]||GENE-EXPRESSION PROFILES ; LYMPH-NODE METASTASIS ; CDNA MICROARRAY ; BREAST-CANCER ; RHO-GTPASES ; PROTEINS ; PROGRESSION ; RHOGDI2|
Introduction: LyGDI is an inhibitor of Rho protein activation by blocking its transformation between guanosine 5′-diphosphate- and guanosine 5′-triphosphate-bound states. The aim of this study was to investigate the usefulness of LyGDI as a biomarker for the detection of ovarian cancer, and its specificity and sensitivity were compared with those of cancer antigen 125 (CA125).
Methods: The serum levels of LyGDI were determined by enzyme-linked immunosorbent assay in 42 patients with ovarian disease, including 30 ovarian cancers and 12 benign ovarian lesions, and 76 healthy controls. The expression of LyGDI was also evaluated by immunohistochemical staining in resected ovarian tissues of these patients.
Results: The serum LyGDI level of cancers was significantly greater than those of the benign and healthy groups (P = 0.002 and P < 0.0001, respectively), whereas no difference was observed between the benign and control groups (P = 0.889). Based upon receiver operating characteristic curve analysis, LyGDI levels were able to distinguish ovarian cancer from benign ovarian disease (P = 0.0001) and healthy control (P G 0.0001; areas under the receiver operating characteristic curves, 0.876 and 0.833, respectively). For ovarian cancers, 83.3% (25/30) or 80.0% (24/30) was identified by serum LyGDI (>= 1.5 ng/mL) alone or by CA125 (>35 U/mL) alone. It is of particular importance to note that all cancer patients were identified by use of both markers, and the specificity was 83.3% for the benign group. Moreover, in early-stage cancers, 88.9% (8/9) had elevated serum LyGDI levels as compared with 44.4% (4/9) elevation of CA125 levels (P = 0.125). Immunohistochemical staining confirmed the expression of LyGDI on cancerous epithelial cells other than benign ovarian epithelium.
Conclusions: These results suggest that LyGDI has significant potential as a marker for detection of ovarian cancer in the patients with ovarian enlargement, including detection of early-stage cancers.
|项目编号||39970763 ; 30471807|
|资助机构||National Science Foundation of China|
|作者单位||1.Peking Univ, Hosp 3, Dept Obstet & Gynecol, Beijing 100191, Peoples R China|
2.Peking Univ, Hlth Sci Ctr, Dept Cell Biol, Beijing 100191, Peoples R China
3.Peking Univ, Hlth Sci Ctr, Dept Pathol, Beijing 100191, Peoples R China
4.Peking Univ, Hlth Sci Ctr, Anal Ctr, Beijing 100191, Peoples R China
5.Peking Univ, Hosp 3, Dept Stat Anal, Beijing 100191, Peoples R China
6.Shanghai Jiao Tong Univ, Dept Oncol, Renji Hosp, Shanghai 200030, Peoples R China
|Zhen, Hongying,Yang, Shaomin,Wu, Hounan,et al. LyGDI is a Promising Biomarker for Ovarian Cancer[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER,2010,20(3):316-322.|
|APA||Zhen, Hongying.,Yang, Shaomin.,Wu, Hounan.,Wang, Shuling.,Lv, Jingqiao.,...&Zhang, Xiaowei.(2010).LyGDI is a Promising Biomarker for Ovarian Cancer.INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER,20(3),316-322.|
|MLA||Zhen, Hongying,et al."LyGDI is a Promising Biomarker for Ovarian Cancer".INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 20.3(2010):316-322.|
|LyGDI is a Promising（1256KB）||期刊论文||出版稿||开放获取||CC BY-NC-SA||浏览 请求全文|